Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Under Pressure As NICE Calls For More Reslizumab Analyses

Executive Summary

UK HTA body NICE has called for clarifications and updated analyses in draft guidance on Teva’s MAb biologic Cinqaero, a decision that may give heart to potential competitors in the race to dominate the eosinophilic asthma market.

Advertisement

Related Content

Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy
Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market
Teva Gets EU Green Light For Reslizumab
Roche Reviewing Next Steps For Lebrikizumab After Mixed Phase III Data
Advair Generic Looms, But GSK Says Growth Will Return Regardless

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097677

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel